We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer said Li uploaded over 12,000 documents to her personal drive and devices shortly before she was set to begin working at Xencor, a Monrovia, Calif.-based biotech. Read More
Philip Dormitzer provided Pfizer scientific leadership for the development of the company’s mRNA-based COVID-19 vaccine co-developed with BioNTech. Read More
A federal appeals court has upheld Mylan’s challenge to a Biogen patent covering the latter’s blockbuster multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate). Read More
The new center is located near two large hospitals and a life sciences cluster that, with 400 companies, is the largest in Europe, AstraZeneca said. Read More
GlaxoSmithKline (GSK) has forged an exclusive license agreement with Arrowhead Pharmaceuticals to develop and commercialize ARO-HSD, Arrowhead’s investigational RNA interference (RNAi) therapeutic currently in a phase 1/2 trial. The deal is potentially worth more than $1 billion. Read More
Arcus is now “well-positioned to accelerate and expand clinical development activities … [for] patients with some of the most difficult to treat cancers, including pancreatic, lung, colon and prostate,” said Arcus CEO Terry Rosen. Read More
Novo Nordisk plans to acquire Dicerna Pharmaceuticals for $3.3 billion, a move that will net Novo Nordisk a ribonucleic acid interference (RNAi) platform for identifying genes that can be targeted to develop drug candidates across many therapeutic areas. Read More
Humira’s increased U.S. price “contrasts starkly to its falling price in every country where Humira currently faces biosimilar competition,” noted David Rind, ICER’s chief medical officer. Read More